Literature DB >> 17711540

Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction.

Kevin J Mortimer1, Anne E Tattersfield, Yufei Tang, Kai Wu, Sarah Lewis, Gunther Hochhaus, Tim W Harrison.   

Abstract

AIMS: To determine whether and to what extent bronchoconstriction affects plasma concentrations of fluticasone and budesonide following inhalation.
METHODS: Twenty people with mild asthma inhaled 1000 microg fluticasone (Accuhaler) plus 800 microg budesonide (Turbohaler) on two visits. On one occasion, prior to drug inhalation, FEV(1) was decreased by at least 25% using inhaled methacholine. Plasma drug concentrations were measured for each drug over 5 h and area under the plasma concentration-time curve (AUC(0,5 h)) compared between visits.
RESULTS: The mean difference in FEV(1) prior to drug inhalation on the 2 days was 33%. AUC(0,5 h) values for fluticasone and budesonide were lower by a median of 60% (IQR 36-75) and 29% (IQR 2-44), respectively, when administered following bronchoconstriction; the reduction was greater for fluticasone than for budesonide, P = 0.007.
CONCLUSIONS: The lower plasma concentrations of fluticasone and, to a lesser extent, budesonide seen when the drugs were inhaled following induced bronchoconstriction, is likely to reflect variations that will occur with fluctuations in airway caliber in asthma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17711540      PMCID: PMC2048552          DOI: 10.1111/j.1365-2125.2007.02856.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects.

Authors:  T W Harrison; A E Tattersfield
Journal:  Thorax       Date:  2003-03       Impact factor: 9.139

2.  SPE/RIA vs LC/MS for measurement of low levels of budesonide in plasma.

Authors:  H Dimova; Y Wang; S Pommery; H Moellmann; G Hochhaus
Journal:  Biomed Chromatogr       Date:  2003-01       Impact factor: 1.902

3.  Inhaled corticosteroids and hip fracture: a population-based case-control study.

Authors:  Richard B Hubbard; Chris J P Smith; Liam Smeeth; Tim W Harrison; Anne E Tattersfield
Journal:  Am J Respir Crit Care Med       Date:  2002-09-25       Impact factor: 21.405

Review 4.  Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids.

Authors:  M Johnson
Journal:  J Allergy Clin Immunol       Date:  1996-01       Impact factor: 10.793

5.  Rapid method for measurement of bronchial responsiveness.

Authors:  K Yan; C Salome; A J Woolcock
Journal:  Thorax       Date:  1983-10       Impact factor: 9.139

6.  Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study.

Authors:  M H Brutsche; I C Brutsche; M Munawar; S J Langley; C M Masterson; P T Daley-Yates; R Brown; A Custovic; A Woodcock
Journal:  Lancet       Date:  2000-08-12       Impact factor: 79.321

7.  Effects of inhaled glucocorticoids on bone density in premenopausal women.

Authors:  E Israel; T R Banerjee; G M Fitzmaurice; T V Kotlov; K LaHive; M S LeBoff
Journal:  N Engl J Med       Date:  2001-09-27       Impact factor: 91.245

8.  Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom.

Authors:  G R G Todd; C L Acerini; R Ross-Russell; S Zahra; J T Warner; D McCance
Journal:  Arch Dis Child       Date:  2002-12       Impact factor: 3.791

9.  Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children.

Authors:  Lone Agertoft; Soren Pedersen
Journal:  Am J Respir Crit Care Med       Date:  2003-07-31       Impact factor: 21.405

10.  Regional lung deposition and clearance of 99mTc-labeled beclomethasone-DLPC liposomes in mild and severe asthma.

Authors:  S M Saari; M T Vidgren; M O Koskinen; V M Turjanmaa; J C Waldrep; M M Nieminen
Journal:  Chest       Date:  1998-06       Impact factor: 9.410

View more
  6 in total

1.  A Systematic Analysis of the Sensitivity of Plasma Pharmacokinetics to Detect Differences in the Pulmonary Performance of Inhaled Fluticasone Propionate Products Using a Model-Based Simulation Approach.

Authors:  Benjamin Weber; Guenther Hochhaus
Journal:  AAPS J       Date:  2015-05-02       Impact factor: 4.009

Review 2.  Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs.

Authors:  Jens Markus Borghardt; Benjamin Weber; Alexander Staab; Charlotte Kloft
Journal:  AAPS J       Date:  2015-04-07       Impact factor: 4.009

3.  A pharmacokinetic simulation tool for inhaled corticosteroids.

Authors:  Benjamin Weber; Guenther Hochhaus
Journal:  AAPS J       Date:  2012-11-10       Impact factor: 4.009

4.  A compartment-quasi-3D multiscale approach for drug absorption, transport, and retention in the human lungs.

Authors:  Ravishekar Ravi Kannan; Narender Singh; Andrzej Przekwas
Journal:  Int J Numer Method Biomed Eng       Date:  2018-01-25       Impact factor: 2.747

5.  Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study.

Authors:  Emir Festic; Vikas Bansal; Ognjen Gajic; Augustine S Lee
Journal:  Mayo Clin Proc       Date:  2014-02       Impact factor: 7.616

6.  The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.

Authors:  Chris Dalby; Tomasz Polanowski; Thomas Larsson; Lars Borgström; Staffan Edsbäcker; Tim W Harrison
Journal:  Respir Res       Date:  2009-10-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.